AgingResearch.NewsJoin free

CStone Pharmaceuticals

CompanyChinaFounded 2015

RORWikidata

CStone Pharmaceuticals develops one asset, in phase 3 (CS1001 in unresectable locally advanced recurrent or metastatic esophageal squamous cell carcinoma). Mostly antibody acting on CD274; based in China, founded in 2015.

1
Asset
Furthest stage
Phase 3
6
Trials
0
Signals

Pipeline

1

  • CS1001

    Anti-PD-L1 monoclonal antibody blocking immune checkpoint inhibition.

    Phase 3, Antibody, CD274, unresectable locally advanced recurrent or metastatic esophageal squamous cell carcinoma, advanced solid tumor (Phase 1)

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Trials7
  • Similar companies6

Intelligence